Carmustine
Drug class: Antineoplastic Agents
Usage of Carmustine
Brain Tumors: Conventional Chemotherapy
Adjunct to radiation therapy following surgery for palliative treatment of malignant glioma (i.e., astrocytoma, ependymoma, medulloblastoma, brainstem glioma) and metastatic brain tumors.
Among several preferred chemotherapeutic regimens for anaplastic astrocytoma and glioblastoma multiforme. Has not been shown to increase survival time, but a trend toward a higher long-term survival rate (e.g., at 18 months) has been observed.
Adjuvant or salvage therapy for oligodendroglioma.
Surgery with or without radiation therapy currently considered standard treatment for ependymoma and medulloblastoma. Radiation therapy considered standard treatment for brainstem glioma.
Brain Tumors: Intracranial Wafer Implant
Adjunct to surgery and radiation for treatment of newly diagnosed high-grade malignant glioma. Among several preferred chemotherapeutic regimens for anaplastic astrocytoma and glioblastoma multiforme.
Adjunct to surgery for treatment of recurrent glioblastoma multiforme.
Multiple Myeloma
Carmustine-containing regimens considered alternative therapy for palliative treatment of multiple myeloma.
Hodgkin’s Disease
Used in combination with other agents as secondary therapy for treatment of refractory or relapsed Hodgkin’s disease.
Combination regimens containing other agents currently are preferred as initial or alternative therapy for this cancer.
Non-Hodgkin’s Lymphoma
Used in combination with other agents as secondary therapy for treatment of refractory or relapsed non-Hodgkin’s lymphomas.
Combination regimens containing other agents currently are preferred as initial or alternative therapy for these cancers.
Melanoma
Has been used alone or in combination therapy for palliative treatment of metastatic melanoma† [off-label]; however, low response rate and substantial toxicity limit this use of carmustine.
Cutaneous T-cell Lymphoma
Used topically† [off-label] for palliative treatment of cutaneous T-cell lymphoma (mycosis fungoides)† [off-label].
Relate drugs
- Abemaciclib (Systemic)
- Acyclovir (Systemic)
- Adenovirus Vaccine
- Aldomet
- Aluminum Acetate
- Aluminum Chloride (Topical)
- Ambien
- Ambien CR
- Aminosalicylic Acid
- Anacaulase
- Anacaulase
- Anifrolumab (Systemic)
- Antacids
- Anthrax Immune Globulin IV (Human)
- Antihemophilic Factor (Recombinant), Fc fusion protein (Systemic)
- Antihemophilic Factor (recombinant), Fc-VWF-XTEN Fusion Protein
- Antihemophilic Factor (recombinant), PEGylated
- Antithrombin alfa
- Antithrombin alfa
- Antithrombin III
- Antithrombin III
- Antithymocyte Globulin (Equine)
- Antivenin (Latrodectus mactans) (Equine)
- Apremilast (Systemic)
- Aprepitant/Fosaprepitant
- Articaine
- Asenapine
- Atracurium
- Atropine (EENT)
- Avacincaptad Pegol (EENT)
- Avacincaptad Pegol (EENT)
- Axicabtagene (Systemic)
- Clidinium
- Clindamycin (Systemic)
- Clonidine
- Clonidine (Epidural)
- Clonidine (Oral)
- Clonidine injection
- Clonidine transdermal
- Co-trimoxazole
- COVID-19 Vaccine (Janssen) (Systemic)
- COVID-19 Vaccine (Moderna)
- COVID-19 Vaccine (Pfizer-BioNTech)
- Crizanlizumab-tmca (Systemic)
- Cromolyn (EENT)
- Cromolyn (Systemic, Oral Inhalation)
- Crotalidae Polyvalent Immune Fab
- CycloSPORINE (EENT)
- CycloSPORINE (EENT)
- CycloSPORINE (Systemic)
- Cysteamine Bitartrate
- Cysteamine Hydrochloride
- Cysteamine Hydrochloride
- Cytomegalovirus Immune Globulin IV
- A1-Proteinase Inhibitor
- A1-Proteinase Inhibitor
- Bacitracin (EENT)
- Baloxavir
- Baloxavir
- Bazedoxifene
- Beclomethasone (EENT)
- Beclomethasone (Systemic, Oral Inhalation)
- Belladonna
- Belsomra
- Benralizumab (Systemic)
- Benzocaine (EENT)
- Bepotastine
- Betamethasone (Systemic)
- Betaxolol (EENT)
- Betaxolol (Systemic)
- Bexarotene (Systemic)
- Bismuth Salts
- Botulism Antitoxin (Equine)
- Brimonidine (EENT)
- Brivaracetam
- Brivaracetam
- Brolucizumab
- Brompheniramine
- Budesonide (EENT)
- Budesonide (Systemic, Oral Inhalation)
- Bulk-Forming Laxatives
- Bupivacaine (Local)
- BuPROPion (Systemic)
- Buspar
- Buspar Dividose
- Buspirone
- Butoconazole
- Cabotegravir (Systemic)
- Caffeine/Caffeine and Sodium Benzoate
- Calcitonin
- Calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate
- Calcium Salts
- Calcium, magnesium, potassium, and sodium oxybates
- Candida Albicans Skin Test Antigen
- Cantharidin (Topical)
- Capmatinib (Systemic)
- Carbachol
- Carbamide Peroxide
- Carbamide Peroxide
- Carmustine
- Castor Oil
- Catapres
- Catapres-TTS
- Catapres-TTS-1
- Catapres-TTS-2
- Catapres-TTS-3
- Ceftolozane/Tazobactam (Systemic)
- Cefuroxime
- Centruroides Immune F(ab′)2
- Cetirizine (EENT)
- Charcoal, Activated
- Chloramphenicol
- Chlorhexidine (EENT)
- Chlorhexidine (EENT)
- Cholera Vaccine Live Oral
- Choriogonadotropin Alfa
- Ciclesonide (EENT)
- Ciclesonide (Systemic, Oral Inhalation)
- Ciprofloxacin (EENT)
- Citrates
- Dacomitinib (Systemic)
- Dapsone (Systemic)
- Dapsone (Systemic)
- Daridorexant
- Darolutamide (Systemic)
- Dasatinib (Systemic)
- DAUNOrubicin and Cytarabine
- Dayvigo
- Dehydrated Alcohol
- Delafloxacin
- Delandistrogene Moxeparvovec (Systemic)
- Dengue Vaccine Live
- Dexamethasone (EENT)
- Dexamethasone (Systemic)
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine (Intravenous)
- Dexmedetomidine (Oromucosal)
- Dexmedetomidine buccal/sublingual
- Dexmedetomidine injection
- Dextran 40
- Diclofenac (Systemic)
- Dihydroergotamine
- Dimethyl Fumarate (Systemic)
- Diphenoxylate
- Diphtheria and Tetanus Toxoids
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Diroximel Fumarate (Systemic)
- Docusate Salts
- Donislecel-jujn (Systemic)
- Doravirine, Lamivudine, and Tenofovir Disoproxil
- Doxepin (Systemic)
- Doxercalciferol
- Doxycycline (EENT)
- Doxycycline (Systemic)
- Doxycycline (Systemic)
- Doxylamine
- Duraclon
- Duraclon injection
- Dyclonine
- Edaravone
- Edluar
- Efgartigimod Alfa (Systemic)
- Eflornithine
- Eflornithine
- Elexacaftor, Tezacaftor, And Ivacaftor
- Elranatamab (Systemic)
- Elvitegravir, Cobicistat, Emtricitabine, and tenofovir Disoproxil Fumarate
- Emicizumab-kxwh (Systemic)
- Emtricitabine and Tenofovir Disoproxil Fumarate
- Entrectinib (Systemic)
- EPINEPHrine (EENT)
- EPINEPHrine (Systemic)
- Erythromycin (EENT)
- Erythromycin (Systemic)
- Estrogen-Progestin Combinations
- Estrogen-Progestin Combinations
- Estrogens, Conjugated
- Estropipate; Estrogens, Esterified
- Eszopiclone
- Ethchlorvynol
- Etranacogene Dezaparvovec
- Evinacumab (Systemic)
- Evinacumab (Systemic)
- Factor IX (Human), Factor IX Complex (Human)
- Factor IX (Recombinant)
- Factor IX (Recombinant), albumin fusion protein
- Factor IX (Recombinant), Fc fusion protein
- Factor VIIa (Recombinant)
- Factor Xa (recombinant), Inactivated-zhzo
- Factor Xa (recombinant), Inactivated-zhzo
- Factor XIII A-Subunit (Recombinant)
- Faricimab
- Fecal microbiota, live
- Fedratinib (Systemic)
- Fenofibric Acid/Fenofibrate
- Fibrinogen (Human)
- Flunisolide (EENT)
- Fluocinolone (EENT)
- Fluorides
- Fluorouracil (Systemic)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Fluticasone (EENT)
- Fluticasone (Systemic, Oral Inhalation)
- Fluticasone and Vilanterol (Oral Inhalation)
- Ganciclovir Sodium
- Gatifloxacin (EENT)
- Gentamicin (EENT)
- Gentamicin (Systemic)
- Gilteritinib (Systemic)
- Glofitamab
- Glycopyrronium
- Glycopyrronium
- Gonadotropin, Chorionic
- Goserelin
- Guanabenz
- Guanadrel
- Guanethidine
- Guanfacine
- Haemophilus b Vaccine
- Hepatitis A Virus Vaccine Inactivated
- Hepatitis B Vaccine Recombinant
- Hetlioz
- Hetlioz LQ
- Homatropine
- Hydrocortisone (EENT)
- Hydrocortisone (Systemic)
- Hydroquinone
- Hylorel
- Hyperosmotic Laxatives
- Ibandronate
- Igalmi buccal/sublingual
- Imipenem, Cilastatin Sodium, and Relebactam
- Inclisiran (Systemic)
- Infliximab, Infliximab-dyyb
- Influenza Vaccine Live Intranasal
- Influenza Vaccine Recombinant
- Influenza Virus Vaccine Inactivated
- Inotuzumab
- Insulin Human
- Interferon Alfa
- Interferon Beta
- Interferon Gamma
- Intermezzo
- Intuniv
- Iodoquinol (Topical)
- Iodoquinol (Topical)
- Ipratropium (EENT)
- Ipratropium (EENT)
- Ipratropium (Systemic, Oral Inhalation)
- Ismelin
- Isoproterenol
- Ivermectin (Systemic)
- Ivermectin (Topical)
- Ixazomib Citrate (Systemic)
- Japanese Encephalitis Vaccine
- Kapvay
- Ketoconazole (Systemic)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (Systemic)
- Ketotifen
- Lanthanum
- Lecanemab
- Lefamulin
- Lemborexant
- Lenacapavir (Systemic)
- Leniolisib
- Letermovir
- Letermovir
- Levodopa/Carbidopa
- LevoFLOXacin (EENT)
- LevoFLOXacin (Systemic)
- L-Glutamine
- Lidocaine (Local)
- Lidocaine (Systemic)
- Linezolid
- Lofexidine
- Loncastuximab
- Lotilaner (EENT)
- Lotilaner (EENT)
- Lucemyra
- Lumasiran Sodium
- Lumryz
- Lunesta
- Mannitol
- Mannitol
- Mb-Tab
- Measles, Mumps, and Rubella Vaccine
- Mecamylamine
- Mechlorethamine
- Mechlorethamine
- Melphalan (Systemic)
- Meningococcal Groups A, C, Y, and W-135 Vaccine
- Meprobamate
- Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
- Methyldopa
- Methylergonovine, Ergonovine
- MetroNIDAZOLE (Systemic)
- MetroNIDAZOLE (Systemic)
- Miltown
- Minipress
- Minocycline (EENT)
- Minocycline (Systemic)
- Minoxidil (Systemic)
- Mometasone
- Mometasone (EENT)
- Moxifloxacin (EENT)
- Moxifloxacin (Systemic)
- Nalmefene
- Naloxone (Systemic)
- Natrol Melatonin + 5-HTP
- Nebivolol Hydrochloride
- Neomycin (EENT)
- Neomycin (Systemic)
- Netarsudil Mesylate
- Nexiclon XR
- Nicotine
- Nicotine
- Nicotine
- Nilotinib (Systemic)
- Nirmatrelvir
- Nirmatrelvir
- Nitroglycerin (Systemic)
- Ofloxacin (EENT)
- Ofloxacin (Systemic)
- Oliceridine Fumarate
- Olipudase Alfa-rpcp (Systemic)
- Olopatadine
- Omadacycline (Systemic)
- Osimertinib (Systemic)
- Oxacillin
- Oxymetazoline
- Pacritinib (Systemic)
- Palovarotene (Systemic)
- Paraldehyde
- Peginterferon Alfa
- Peginterferon Beta-1a (Systemic)
- Penicillin G
- Pentobarbital
- Pentosan
- Pilocarpine Hydrochloride
- Pilocarpine, Pilocarpine Hydrochloride, Pilocarpine Nitrate
- Placidyl
- Plasma Protein Fraction
- Plasminogen, Human-tmvh
- Pneumococcal Vaccine
- Polymyxin B (EENT)
- Polymyxin B (Systemic, Topical)
- PONATinib (Systemic)
- Poractant Alfa
- Posaconazole
- Potassium Supplements
- Pozelimab (Systemic)
- Pramoxine
- Prazosin
- Precedex
- Precedex injection
- PrednisoLONE (EENT)
- PrednisoLONE (Systemic)
- Progestins
- Propylhexedrine
- Protamine
- Protein C Concentrate
- Protein C Concentrate
- Prothrombin Complex Concentrate
- Pyrethrins with Piperonyl Butoxide
- Quviviq
- Ramelteon
- Relugolix, Estradiol, and Norethindrone Acetate
- Remdesivir (Systemic)
- Respiratory Syncytial Virus Vaccine, Adjuvanted (Systemic)
- RifAXIMin (Systemic)
- Roflumilast (Systemic)
- Roflumilast (Topical)
- Roflumilast (Topical)
- Rotavirus Vaccine Live Oral
- Rozanolixizumab (Systemic)
- Rozerem
- Ruxolitinib (Systemic)
- Saline Laxatives
- Selenious Acid
- Selexipag
- Selexipag
- Selpercatinib (Systemic)
- Sirolimus (Systemic)
- Sirolimus, albumin-bound
- Smallpox and Mpox Vaccine Live
- Smallpox Vaccine Live
- Sodium Chloride
- Sodium Ferric Gluconate
- Sodium Nitrite
- Sodium oxybate
- Sodium Phenylacetate and Sodium Benzoate
- Sodium Thiosulfate (Antidote) (Systemic)
- Sodium Thiosulfate (Protectant) (Systemic)
- Somatrogon (Systemic)
- Sonata
- Sotorasib (Systemic)
- Suvorexant
- Tacrolimus (Systemic)
- Tafenoquine (Arakoda)
- Tafenoquine (Krintafel)
- Talquetamab (Systemic)
- Tasimelteon
- Tedizolid
- Telotristat
- Tenex
- Terbinafine (Systemic)
- Tetrahydrozoline
- Tezacaftor and Ivacaftor
- Theophyllines
- Thrombin
- Thrombin Alfa (Recombinant) (Topical)
- Timolol (EENT)
- Timolol (Systemic)
- Tixagevimab and Cilgavimab
- Tobramycin (EENT)
- Tobramycin (Systemic)
- TraMADol (Systemic)
- Trametinib Dimethyl Sulfoxide
- Trancot
- Tremelimumab
- Tretinoin (Systemic)
- Triamcinolone (EENT)
- Triamcinolone (Systemic)
- Trimethobenzamide
- Tucatinib (Systemic)
- Unisom
- Vaccinia Immune Globulin IV
- Valoctocogene Roxaparvovec
- Valproate/Divalproex
- Valproate/Divalproex
- Vanspar
- Varenicline (Systemic)
- Varenicline (Systemic)
- Varenicline Tartrate (EENT)
- Vecamyl
- Vitamin B12
- Vonoprazan, Clarithromycin, and Amoxicillin
- Wytensin
- Xyrem
- Xywav
- Zaleplon
- Zirconium Cyclosilicate
- Zolpidem
- Zolpidem (Oral)
- Zolpidem (Oromucosal, Sublingual)
- ZolpiMist
- Zoster Vaccine Recombinant
- 5-hydroxytryptophan, melatonin, and pyridoxine
How to use Carmustine
General
Administration
Administer by IV infusion or intracranially as wafer implants.
Has been administered by intra-arterial† [off-label] (into the carotid artery) route; however, such administration has been associated with ocular toxicity (blindness), fatal encephalopathy, and inferior survival.
Has been administered topically† [off-label] as a 0.05–0.4% hydroalcoholic solution or as an ointment, but dosage forms for such use are not commercially available in US; consult specialized references.
IV Administration
For solution and drug compatibility information, see Compatibility under Stability.
Vials are for single use only.
Use glass containers for administration.
Handle cautiously (e.g., use gloves); avoid exposure during handling of powder and preparation of IV solution.
If skin or mucosal contact occurs, immediately wash affected area(s) thoroughly with soap and water.
ReconstitutionAdd 3 mL of diluent provided by manufacturer (sterile dehydrated [absolute] alcohol) to vial containing 100 mg of carmustine; then add 27 mL of sterile water for injection. Resulting solution contains 3.3 mg/mL carmustine in 10% ethanol.
DilutionDilute with 5% Dextrose injection.
Rate of AdministrationAdminister by IV infusion over 1–2 hours. More rapid administration associated with adverse effects. (See Local Effects under Cautions.)
Intracranial Wafer Implant
Handle with care (cytotoxic material); use double surgical gloves and discard outer gloves into biohazard waste container after use.
Wafers broken in half may be used; discard in biohazard container if broken in >2 pieces.
Deliver aluminum foil laminate pouches containing wafer to operating room; do not open until ready to implant. Outside surface of outer foil pouch is not sterile.
Use surgical instrument dedicated to handling carmustine wafers to implant the wafers.
Implant intracranially in the resection cavity following surgical resection of brain tumor.
Place oxidized regenerated cellulose (Surgicel) over wafers to secure them against surface of resection cavity. Following placement of wafers, irrigate resection cavity and close dura in a watertight fashion to minimize risk of CSF leak.
Dosage
Adults
Brain Tumors IVAs monotherapy in previously untreated patients, 150–200 mg/m2 administered as a single dose or in divided doses (e.g., 75–100 mg/m2 on 2 successive days) at intervals of at least 6 weeks.
Reduce dosage if used in combination with other myelosuppressive drugs or in patients with compromised bone marrow function.
Adjust subsequent dosages based on nadir blood counts from preceding dose (see Dosage Modification for Toxicity under Dosage and Administration).
Intracranial Wafer ImplantUp to 8 wafers (total carmustine dose: 61.6 mg) intracranially to cover as much of the resection cavity as possible (slight overlapping permissible). If size and shape of cavity will not allow placement of 8 wafers, use maximum possible number.
Do not place >8 wafers intracranially per surgical procedure.
In clinical trials, chemotherapy was withheld for at least 4 weeks (6 weeks for nitrosoureas) prior to and 2 weeks after surgery; external beam radiation therapy was administered no sooner than 3 weeks after surgery.
Multiple Myeloma IVAs monotherapy in previously untreated patients, 150–200 mg/m2 administered as a single dose or in divided doses (e.g., 75–100 mg/m2 on 2 successive days) at intervals of at least 6 weeks.
Reduce dosage if used in combination with other myelosuppressive drugs or in patients with compromised bone marrow function.
Adjust subsequent dosages based on nadir blood counts from preceding dose (see Dosage Modification for Toxicity under Dosage and Administration).
Hodgkin’s Disease IVAs monotherapy in previously untreated patients, 150–200 mg/m2 administered as a single dose or in divided doses (e.g., 75–100 mg/m2 on 2 successive days) at intervals of at least 6 weeks.
Reduce dosage if used in combination with other myelosuppressive drugs or in patients with compromised bone marrow function.
Adjust subsequent dosages based on nadir blood counts from preceding dose (see Dosage Modification for Toxicity under Dosage and Administration).
Non-Hodgkin’s Lymphoma IVAs monotherapy in previously untreated patients, 150–200 mg/m2 administered as a single dose or in divided doses (e.g., 75–100 mg/m2 on 2 successive days) at intervals of at least 6 weeks.
Reduce dosage if used in combination with other myelosuppressive drugs or in patients with compromised bone marrow function.
Adjust subsequent dosages based on nadir blood counts from preceding dose (see Dosage Modification for Toxicity under Dosage and Administration).
Cutaneous T-cell Lymphoma† TopicalUsual topical dosage is 10 mg once daily for 7–14 weeks (maximum: 17 weeks). If response is inadequate, after a rest interval of 6 weeks, administer second course of topical therapy with 20 mg once daily for 4–8 weeks, as tolerated.
Topical dosage form not commercially available in US; consult specialized references for specific information on topical use.
Dosage Modification for Toxicity
Conventional ChemotherapyDo not administer repeat courses until leukocyte count >4000/mm3, platelet count >100,000/mm3, and an adequate number of neutrophils is present on peripheral blood smear.
Bone marrow toxicity is cumulative; adjust subsequent dosages based on nadir blood counts from previous dose.
Table 1. Dosage Adjustments for Hematologic Toxicities Based on Nadir After Prior Dose (manufacturer’s recommendations)Leukocytes (cells/mm3)
Platelets (cells/mm3)
Percentage of Prior Dose to be Given
>4000
>100,000
100%
3000–3999
75,000–99,999
100%
2000–2999
25,000–74,999
70%
<2000
<25,000
50%
Alternatively, to avoid potential overdosage associated with manufacturer’s suggested modifications, some clinicians recommend reducing subsequent dosage by 25% when platelet nadirs are 50,000–74,999/mm3; by 50% for nadirs of 25,000–49,999/mm3; and by 75% for nadirs <25,000/mm3.
Prescribing Limits
Adults
Brain Tumors Intracranial Wafer ImplantMaximum 8 wafers per surgical procedure.
Special Populations
Geriatric Patients
Select IV dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy. (See Geriatric Use under Cautions.)
Warnings
Contraindications
Warnings/Precautions
Warnings
Hematologic EffectsRisk of myelosuppression (e.g., thrombocytopenia, leukopenia) following IV carmustine; effects are delayed and cumulative. (See Boxed Warning.) Thrombocytopenia generally more severe than leukopenia but both considered dose-limiting toxicities. Anemia reported less frequently and is less severe.
Following IV administration, thrombocytopenia and leukopenia occur at approximately 4 and 5–6 weeks, respectively, and persist for 1–2 weeks.
Repeated dosing associated with more severe and more prolonged myelosuppression.
Use with caution in patients with depressed platelet, leukocyte, or erythrocyte counts.
Pulmonary EffectsWith IV carmustine, risk of dose-related, sometimes fatal, pulmonary toxicity (characterized by pulmonary infiltrates and/or fibrosis). (See Boxed Warning.) Risk factors include prolonged therapy (with cumulative doses >1400 mg/m2) and history of lung disease.
Risk of delayed-onset pulmonary fibrosis (occurred up to 17 years after treatment during childhood and early adolescence); possible reduction of pulmonary function or death. (See Pediatric Use under Cautions.)
Perform pulmonary function tests prior to initiation of and frequently during therapy. Patients with baseline forced vital capacity (FVC) or pulmonary diffusion capacity for carbon monoxide (DLCO) <70% of predicted value are particularly at risk.
Secondary MalignanciesRisk of secondary malignancies following long-term use of nitrosoureas.
Intracranial Implant ComplicationsIntracerebral mass effect unresponsive to corticosteroids reported, including one case leading to brain herniation. Brain edema with mass effect (due to tumor recurrence, intracranial infection, or necrosis) may necessitate reoperation and, in some cases, removal of wafer or wafer remnants.
Risk of seizures; median time to onset is 3.5 days.
Formation of tumor bed cyst unresponsive to high-dose corticosteroids reported; required reoperation for drainage following implantation of carmustine wafers.
Monitor patients closely for potential complications of craniotomy (e.g., seizures, intracranial infections, abnormal wound healing, brain edema).
Fetal/Neonatal Morbidity and MortalityPossible fetal harm; teratogenicity and embryotoxicity demonstrated in animals. Avoid pregnancy during therapy. If used during pregnancy or if patient becomes pregnant, apprise of potential fetal hazard.
Major Toxicities
Local EffectsRapid IV infusion may result in intensive flushing of the skin and suffusion of the conjunctiva; these effects occur within 2 hours and persist for 4 hours after IV administration. Also associated with intense pain and burning at injection site; thrombosis is rare.
With intracranial wafer implant, wound dehiscence; delayed wound healing; subdural, subgaleal, or wound effusions; and CSF leak reported.
Infectious ComplicationsWith intracranial wafer implant, abscess, meningitis, and pneumonia reported. Sepsis reported but causal relationship not established.
GI EffectsWith IV carmustine, dose-related nausea and vomiting reported within 2 hours and persisting for 4–6 hours. Premedication with antiemetics may diminish or prevent.
Hepatic EffectsAfter IV therapy, reversible increases in serum transaminase, alkaline phosphatase, and bilirubin concentrations reported. Possible hepatic dysfunction. Monitor hepatic function periodically.
Renal EffectsAfter prolonged IV therapy (with large cumulative doses), progressive azotemia, decrease in kidney size, and renal failure reported. Kidney damage reported occasionally in patients receiving lower total doses. Monitor renal function periodically.
General Precautions
IV TherapyEvaluate carmustine benefits against possible risks. Most adverse effects are reversible if detected early with appropriate management (e.g., dosage reduction, discontinuance, appropriate corrective measures). Reinstitute with caution, considering risks and benefits.
Risk of transient hyperpigmentation of skin with accidental dermal exposure; immediately wash exposed skin or mucosa.
Intracranial Wafer ImplantRisk of wafer migration from surgical resection cavity into ventricular system, leading to obstructive hydrocephalus. If communication between surgical resection cavity and ventricular system is larger than diameter of wafers, close such communication prior to implantation.
Enhancement in brain tissue surrounding resection cavity (demonstrated by CT scan or MRI) following intracranial implantation may represent edema and inflammation caused by wafer or tumor progression.
Therapy MonitoringWith IV therapy, monitor CBCs weekly during and for at least 6 weeks following each dose. Also monitor pulmonary, hepatic, and renal function tests periodically during treatment.
Specific Populations
PregnancyCategory D. (See Fetal/Neonatal Morbidity and Mortality under Cautions.)
LactationNot known whether carmustine is distributed into milk. Discontinue nursing because of potential risk to nursing infants. Not known whether constituents of polifeprosan 20 copolymer (i.e., carboxyphenoxypropane, sebacic acid) intracranial wafer are distributed into milk.
Pediatric UseSafety and efficacy of IV carmustine not established in children. Fatal pulmonary fibrosis reported with delayed onset up to 17 years following IV treatment of brain tumors during childhood or adolescence. Extremely high risk of fatal pulmonary toxicity, particularly in children <5 years of age at initial treatment; carefully weigh benefits and risks of therapy in pediatric patients.
Safety and efficacy of intracranial wafer implant not established in pediatric patients.
Geriatric UseInsufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults. Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and potential for concomitant disease and drug therapy.
Systemic carmustine substantially eliminated by kidneys; monitor renal function periodically since geriatric patients are more likely to have decreased renal function.
Common Adverse Effects
For IV carmustine, pulmonary infiltrates and/or fibrosis, thrombocytopenia, leukopenia, anemia, nausea, vomiting, hepatic and renal toxicity. (See Warnings/Precautions under Cautions.)
For intracranial wafer, hemiplegia, seizures, confusion, brain edema, headache, asthenia, nausea, vomiting, constipation, infection, fever, aphasia, abnormal healing, depression, pain, rash, somnolence, speech disorder, deep thrombophlebitis, alopecia.
What other drugs will affect Carmustine
Intracranial Wafer
No formal drug interaction studies to date. In clinical trials, chemotherapy was withheld for at least 4 weeks (6 weeks for nitrosoureas) prior to and 2 weeks after surgery. Implantation in conjunction with radiotherapy does not appear to have any short-term or chronic toxicities; in clinical trials, external beam radiation therapy was administered >3 weeks after surgery.
Specific Drugs
Drug
Interaction
Comments
Cimetidine
Potentiation of neutropenic and thrombocytopenic effect of carmustine
Mitomycin
Possible changes in tear films, with subsequent damage of corneal and conjunctival epithelium
Phenytoin
Possible decreased serum phenytoin concentrations
Monitor serum phenytoin concentrations carefully and adjust dosage accordingly
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions